Drug Profile

Ponatinib - Incyte Corporation/Otsuka Pharmaceutical/Takeda

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ARIAD Pharmaceuticals
Developer Fundacion CRIS de Investigacion para Vencer el Cancer; Incyte Biosciences International; Incyte Corporation; Otsuka Beijing Research Institute; Otsuka Pharmaceutical; Takeda; University of Birmingham
Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Chronic myeloid leukaemia
New Molecular Entity Yes

Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Phase I/II Acute myeloid leukaemia; Haematological malignancies; Solid tumours
Discontinued Gastrointestinal stromal tumours

25 Apr 2025 Efficacy and adverse events data from phase III PhALLCON trial in Acute lymphoblastic leukaemia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
25 Apr 2025 Takeda completes the phase II OPTIC trial in Chronic myeloid leukaemia (Second-line therapy or greater) in Argentina, Australia, Belgium, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Italy, Poland, Portugal, South Korea, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, US, UK (NCT02467270)
15 Jan 2025 Takeda terminates a phase-I/II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (In adults, In children, In infants, In adolescents, Second-line therapy or greater) in United Kingdom, in the US, Argentina, Australia, Brazil, China, Czech Republic, France, Italy, South Korea, Mexico, Spain, Poland, Portugal and the Netherlands (PO) due to dose-limiting toxicities (NCT04501614) (EudraCT2019-002549-39)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com